Takeda Taps Ultragenyx To Step Up Rare Disease Efforts
This article was originally published in PharmAsia News
In its second deal in recent days, Takeda is moving more decisively into the rare disease space through a licensing and collaborative R&D alliance with the specialist US firm Ultragenyx.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.